Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Montazeri P, Fossati S, Clemente DBP, Cirugeda L, Elosua R, Fernandez-Barres S, Fochs S, Garcia-Esteban R, Marquez S, Pey N, Nawrot TS, Vrijheid M. Early-childhood BMI trajectories in relation to preclinical cardiovascular measurements in adolescence. J Dev Orig Hlth Dis. 2022 Jun;13(3):322-9. doi: 10.1017/S2040174421000441
Wise LA, Troisi R, Hatch EE, Titus LJ, Rothman KJ, Harlow BL. Prenatal diethylstilbestrol exposure and reproductive hormones in premenopausal women. J Dev Orig Hlth Dis. 2015 Jun;6(3):208-16.